Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

AllianzGI Partners with The Sea Cleaners to Combat Plastic Pollution in the World’s Oceans

Published

on

Reading Time: 6 minutes

  • The Sea Cleaners’ focus on ocean preservation and pollution
    education a natural fit with AllianzGI’s commitment to Sustainability
  • Five-year partnership will offer engagement opportunities for
    AllianzGI’s clients and colleagues, and support the launch of ‘The
    Manta’, a revolutionary new ship, combining several renewable
    technologies to reduce its carbon footprint, capable of collecting
    10,000 tonnes of plastic macro-waste a year

LONDON–(BUSINESS WIRE)–Allianz Global Investors, one of the world’s leading active investment
managers, announced today that it has entered into a five-year
partnership with The Sea Cleaners, a new project designed to combat
plastic pollution in the world’s oceans. AllianzGI’s support for The Sea
Cleaners is a natural fit with the firm’s commitment to Sustainable
investing, with the partnership also set to open up new engagement
opportunities for AllianzGI’s colleagues and clients, many of whom are
already actively working to combat plastic waste.

Partnering with AllianzGI will support the development of ‘The Manta’,
The Sea Cleaners’ giant new waste collection ship. Measuring in at 70
metres long, 49 metres wide and 61 metres high, The Manta is expected to
take to the seas in 2022. It will use state-of-the-art technology to
collect plastic macro-debris in high density areas like coastlines and
estuaries before they break up and disperse and irreversibly damage
bio-diversity. As well as mass collecting discarded plastic, the ship,
powered by wind turbines, solar panels and automized rigs, will conduct
cutting-edge scientific research, with The Sea Cleaners providing open
source data. One energy recovery unit will also convert non-recyclable
plastics to run the ship and the on-board factory.

On land, The Sea Cleaners work to raise awareness among future
generations of the harm caused by plastic pollution through a wide range
of activities in schools and fairs. As part of this new partnership,
AllianzGI colleagues will have the chance to participate in events with
The Sea Cleaners’ team focused on reducing plastic pollution and leaders
from The Sea Cleaners will attend and support AllianzGI’s range of
Sustainability events.

Thorsten Heymann, Global Head of Strategy at AllianzGI, said:

”A shocking 9 million tonnes of plastic are dumped in the ocean every
year – that’s about 300kg per second. As an active, long-term investor,
with sustainable investing in our DNA, we want to play an active role in
combatting the scourge of plastic pollution, a common cause we share
with The Sea Cleaners. Together, we can help protect the oceans for
future generations.

“This partnership is something we are passionate about for two
reasons: firstly, it resonates with a critical part of our value
proposition for clients, reflecting our desire to take a truly holistic
approach to investing sustainably: and secondly, the joint journey will
provide new ways for our colleagues and clients to engage with a topic
that we know they care about a great deal.”

Yvan Bourgnon, President-Founder of The Sea Cleaners, said:

“Ocean plastic pollution is an ecological catastrophe and we are
delighted to make this partnership with AllianzGI, because their values
and sustainability scope are very closely aligned with ours. Innovation,
international and long-term action, sustainable development,
biodiversity protection, education: let’s put people back at the heart
of important ecological challenges. We are proud to work on this
exciting mission and to build together a story about saving the oceans
with a partner like AllianzGI.”

As part of a drive to reduce plastic use across its global business,
AllianzGI is running internal campaigns to reduce its use of single-use
plastics including introducing ‘Plastic Free Tuesdays’ in its London
office, while colleagues have also taken part in beach clean-up
exercises at Baker Beach in San Francisco, Lamma Island in Hong Kong and
Taiwan’s ‘Coastal Cleanup’. AllianzGI’s Hong Kong office was recently
awarded the “Hong Kong Green Organisation Certification” in recognition
of its active participation in adopting various environmental practices,
including reducing its use of plastics, and promoting a green workplace.

AllianzGI is a pioneer in Sustainable investing. For the last two years,
AllianzGI has received an A+ for its overarching approach to ESG
Strategy and Governance from the Principles for Responsible Investment
(PRI). AllianzGI recently appointed Beatrix Anton-Groenemeyer as its
first Chief Sustainability Officer. This new role, which reports
directly to CEO Andreas Utermann, further underscores the importance of
sustainability to AllianzGI and its clients.

All of AllianzGI’s EUR 535bn of Assets under Management are ESG
(Environmental, Social & Governance) informed, with AllianzGI’s
highly-developed, active programme of engagement, stewardship and
proprietary research available to all investment professionals across
AllianzGI. AllianzGI is committed to, and in the process of, embedding
ES&G factors across all of its investment strategies, with Integrated
ESG already applicable to EUR 118bn of the assets AllianzGI manages. In
addition, as well as managing EUR 22bn in dedicated SRI strategies,
AllianzGI manages around EUR 6bn of impact investments.

About Allianz Global Investors

Allianz Global Investors is a leading active asset manager with over 770
investment professionals in 25 offices worldwide and managing more than
EUR 535 billion in assets for individuals, families and institutions*.

Active is the most important word in our vocabulary. Active is how we
create and share value with clients. We believe in solving, not selling,
and in adding value beyond pure economic gain. We invest for the long
term, employing our innovative investment expertise and global
resources. Our goal is to ensure a superior experience for our clients,
wherever they are based and whatever their investment needs.

Active is: Allianz Global Investors

*Data as at 31 March 2019

About The Sea Cleaners

Created in 2016 by the skipper Yvan Bourgnon, The Sea Cleaners is a
general interest association looking after the preservation of the
oceans. The Sea Cleaners teams are dedicated to the reduction of plastic
pollution, and they have a preventive and corrective vision, acting both
on land and at sea. To succeed in this challenge, they have launched an
innovative project : The Manta ship will be the first ocean going vessel
capable of collecting and mass-treating floating ocean waste before it
breaks up. Observer Member of the UN Environment, and supported by the
Albert Foundation of Monaco, the association The Sea Cleaners has set
objectives that revolve around four areas : Environment, Circular
economy, Education and Science.

Disclaimer

Environmental, Social and Governance (ESG) strategies consider factors
beyond traditional financial information to select securities or
eliminate exposure which could result in relative investment performance
deviating from other strategies or broad market benchmarks.

Investing involves risk. The value of an investment and the income from
it will fluctuate and investors may not get back the principal invested.
Past performance is not indicative of future performance. This is a
marketing communication. It is for informational purposes only. This
document does not constitute investment advice or a recommendation to
buy, sell or hold any security and shall not be deemed an offer to sell
or a solicitation of an offer to buy any security.

The views and opinions expressed herein, which are subject to change
without notice, are those of the issuer or its affiliated companies at
the time of publication. Certain data used are derived from various
sources believed to be reliable, but the accuracy or completeness of the
data is not guaranteed and no liability is assumed for any direct or
consequential losses arising from their use. The duplication,
publication, extraction or transmission of the contents, irrespective of
the form, is not permitted.

This material has not been reviewed by any regulatory authorities. In
mainland China, it is used only as supporting material to the offshore
investment products offered by commercial banks under the Qualified
Domestic Institutional Investors scheme pursuant to applicable rules and
regulations. This communication’s sole purpose is to inform and does not
under any circumstance constitute promotion or publicity of Allianz
Global Investors products and/or services in Colombia or to Colombian
residents pursuant to part 4 of Decree 2555 of 2010. This communication
does not in any way aim to directly or indirectly initiate the purchase
of a product or the provision of a service offered by Allianz Global
Investors. Via reception of his document, each resident in Colombia
acknowledges and accepts to have contacted Allianz Global Investors via
their own initiative and that the communication under no circumstances
does not arise from any promotional or marketing activities carried out
by Allianz Global Investors. Colombian residents accept that accessing
any type of social network page of Allianz Global Investors is done
under their own responsibility and initiative and are aware that they
may access specific information on the products and services of Allianz
Global Investors. This communication is strictly private and
confidential and may not be reproduced. This communication does not
constitute a public offer of securities in Colombia pursuant to the
public offer regulation set forth in Decree 2555 of 2010. This
communication and the information provided herein should not be
considered a solicitation or an offer by Allianz Global Investors or its
affiliates to provide any financial products in Panama, Peru, and
Uruguay.

This document is being distributed by the following Allianz Global
Investors companies: Allianz Global Investors U.S. LLC, an investment
adviser registered with the U.S. Securities and Exchange Commission;
Allianz Global Investors Distributors LLC, distributor registered with
FINRA, is affiliated with Allianz Global Investors U.S. LLC; Allianz
Global Investors GmbH, an investment company in Germany, authorized by
the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin);
Allianz Global Investors (Schweiz) AG, licensed by FINMA (www.finma.ch)
for distribution and by OAKBV (Oberaufsichtskommission berufliche
Vorsorge) for asset management related to occupational pensions in
Switzerland; Allianz Global Investors Asia Pacific Ltd., licensed by the
Hong Kong Securities and Futures Commission; Allianz Global Investors
Singapore Ltd., regulated by the Monetary Authority of Singapore
[Company Registration No. 199907169Z]; Allianz Global Investors Japan
Co., Ltd., registered in Japan as a Financial Instruments Business
Operator [Registered No. The Director of Kanto Local Finance Bureau
(Financial Instruments Business Operator), No. 424, Member of Japan
Investment Advisers Association and Investment Trust Association,
Japan];and Allianz Global Investors Taiwan Ltd., licensed by Financial
Supervisory Commission in Taiwan. 864007

Contacts

Alastair Fairbrother
Tel. 44 020 3246 7432

Sarah Einig
Tel. 44 020 3246 7846

Vivi McDuell
Tel. 44 020 3246 7251

Email: [email protected]

David Taieb
Tel 33 661 558 401
Email: [email protected]

Antoine Rodat
Tel 33 664 626 958
Email: [email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives

Published

on

Continue Reading

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania